Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine

06-05-2024 | Dermatomyositis | Clinical Vignette

Anti-TIF1-γ Antibody-Positive Dermatomyositis Leading to Identification of Diffuse Large B-Cell Lymphoma

Authors: Takuya Otsuki, MD, PhD, Kosuke Ishizuka, MD, PhD, Hiromitsu Eto, MD, Hiroyasu Nakano, MD, Yo Kato, MD, PhD, Hiroshi Sudo, MD, Iori Motohashi, MD, MPH, Kenya Ie, MD, PhD, MPH, Yoshiyuki Ohira, MD, PhD, Chiaki Okuse, MD, PhD

Published in: Journal of General Internal Medicine

Login to get access

Excerpt

Older adults with dermatomyositis positive for anti-transcription intermediary factor 1-gamma (anti-TIF-1γ) antibodies have a high risk of malignancies, including hematologic malignancies such as lymphoma. Here, we present a case of dermatomyositis in a 69-year-old man, who was subsequently diagnosed with diffuse large B-cell lymphoma following two bone marrow biopsies. …
Literature
1.
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955-64.CrossRefPubMed
2.
3.
Kotobuki Y, Tonomura K, Fujimoto M. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis. Immunol Med. 2021;44(1):23-9.CrossRefPubMed
4.
Harada Y, Tominaga M, Iitoh E, et al. Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy. J Clin Med. 2022;11:1925.CrossRefPubMedPubMedCentral
5.
Best M, Molinari N, Chasset F, Vincent T, Cordel N, Bessis D. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2019;99:256-62.CrossRefPubMed
6.
Fiorentino DF, Kuo K, Chung L, Zaba L, Li Shufeng, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72:449-55.CrossRefPubMedPubMedCentral
7.
Mugii N, Hasegawa M, Matsushita T, et al. Oropharyngeal dysphagia in dermatomyositis: Associations with clinical and laboratory features including autoantibodies. PLoS One. 2016;11:e0154746.CrossRefPubMedPubMedCentral
8.
Weinreb SF, Piersiala K, Hillel AT, Akst LM, Best SR. Dysphonia and dysphagia as early manifestations of autoimmune inflammatory myopathy. Am J Otolaryngol. 2021;42(1):102747.CrossRefPubMed
9.
Nishigori K, Yamamoto T, Yokozeki H. Vesiculo-bullous dermatomyositis: Report of three cases. Dermatol Online J. 2009;15(4):6.CrossRefPubMed
10.
Ono R, Kumagae T, Igasaki M, Murata T, Yoshizawa M, Kitagawa I. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature. J Med Case Rep. 2021;15(1):142.CrossRefPubMedPubMedCentral
11.
Aggarwal R, Schessl J, Charles-Schoeman C, et al. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024;26(1):27.CrossRefPubMedPubMedCentral
12.
Kamperman RG, Bogaards JA, Evers SW, et al. Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial. BMJ Open. 2023;13(7):e067435.CrossRefPubMedPubMedCentral
13.
Oldroyd AGS, Callen JP, Chinoy H, et al. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol. 2023;19(12):805-17.CrossRefPubMed
14.
Aggarwal R, Rider LG, Ruperto N, et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheu. Ann Rheum Dis. 2017;76(5):792-801.CrossRefPubMed
15.
Murakami J, Arita K, Wada A, et al. Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions. Mol Clin Oncol. 2019;11(5):474-82.PubMedPubMedCentral
16.
Aucagne R, Droin N, Paggetti J, et al. Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest. 2011;121:2361-70.CrossRefPubMedPubMedCentral
17.
Wang E, Kawaoka S, Roe JS, et al. The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer. Elife. 2015;4:e06377.CrossRefPubMedPubMedCentral
18.
Barreno-Rocha SG, Guzmán-Silahua S, Cardona-Muñoz EG, et al. Frequency of Autoantibodies on Non-Hodgkin Lymphoma. Healthcare (Basel). 2023;11(15):2210.CrossRefPubMedPubMedCentral
19.
Kan E, Levi I, Benharroch D. Alterations in the primary diagnosis of lymphomas pretreated with corticosteroid agents. Leuk Lymphoma. 2011;52:425-8.CrossRefPubMed
20.
Kam KL, Brooker SM, Mao Q, et al. Newly diagnosed enhancing lesions: Steroid initiation may impede diagnosis of lymphoma involving the central nervous system. J Clin Neurosci. 2020;81:61-4.CrossRefPubMed
Metadata
Title
Anti-TIF1-γ Antibody-Positive Dermatomyositis Leading to Identification of Diffuse Large B-Cell Lymphoma
Authors
Takuya Otsuki, MD, PhD
Kosuke Ishizuka, MD, PhD
Hiromitsu Eto, MD
Hiroyasu Nakano, MD
Yo Kato, MD, PhD
Hiroshi Sudo, MD
Iori Motohashi, MD, MPH
Kenya Ie, MD, PhD, MPH
Yoshiyuki Ohira, MD, PhD
Chiaki Okuse, MD, PhD
Publication date
06-05-2024
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-024-08794-8
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits